UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 21, 2012

 

 

SPECTRUM PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware		001-35006		93-0979187
(State or other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
11500 S. Eastern Ave., Ste. 240, Henderson, NV				89052
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s telephone number, including area code: (702) 835-6300

Not Applicable

(Former name or former address if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

Item 8.01 Other Events.

On September 21, 2012, our collaboration partner for belinostat, TopoTarget A/S, disclosed preliminary results for the pivotal phase 2 BELIEF trial. Spectrum continues to collect and analyze data from this trial. Database lock is expected to occur by the end of the fourth quarter, following which a definitive objective response rate will be determined. We also look forward to a required meeting with the FDA once a definitive objective response rate has been reached. Upon positive data and FDA agreement, the company expects to file the NDA application in 2013.

 

2

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 21, 2012

 

				SPECTRUM PHARMACEUTICALS, INC.
				By:		/s/ Brett L. Scott
						Senior Vice President and Acting Chief
						Financial Officer